 |
BioWorld-International-2010-12-15
Disappointing Animal Study is 'No Reason to Give Up on p53'
Intercell Plunges on Phase III Miss; Restructuring to Come
Shares in Intercell AG plummeted 40 percent Monday on news that its patch-based vaccine for traveler's diarrhea failed to demonstrate efficacy in two studies, a Phase III trial in Central America and a Phase II pilot study in India. (BioWorld International)